2.2 Dementia-Related Psychosis

Early Stage Clinical Programs


ACP-044*

ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic. The mechanism of action is thought to interrupt multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a by-product of tissue damage. We are initiating a Phase 2 clinical program in models of acute and chronic pain in the first half of 2021.

ACP-319*

Highly selective positive allosteric modulators (PAMs) of the M1 subtype of the muscarinic acetylcholine receptor may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders. In our M1 PAM program we are focused on advancing a portfolio of early stage candidates, including our lead candidate which is in early Phase 1 trials.

*The safety and efficacy of these investigational agents have not been established or approved by the FDA.